165 related articles for article (PubMed ID: 32681472)
1. Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.
Beeslaar J; Peyrani P; Absalon J; Maguire J; Eiden J; Balmer P; Maansson R; Perez JL
Infect Dis Ther; 2020 Sep; 9(3):625-639. PubMed ID: 32681472
[TBL] [Abstract][Full Text] [Related]
2. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
3. MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
Beeslaar J; Absalon J; Anderson AS; Eiden JJ; Balmer P; Harris SL; Jones TR; O'Neill RE; Pregaldien JL; Radley D; Maansson R; Ginis J; Srivastava A; Perez JL
Infect Dis Ther; 2020 Sep; 9(3):641-656. PubMed ID: 32700260
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Marshall HS; Vesikari T; Richmond PC; Wysocki J; Szenborn L; Beeslaar J; Maguire JD; Balmer P; O'Neill R; Anderson AS; Prégaldien JL; Maansson R; Jiang HQ; Perez JL
Lancet Infect Dis; 2023 Jan; 23(1):103-116. PubMed ID: 36087588
[TBL] [Abstract][Full Text] [Related]
6. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
[TBL] [Abstract][Full Text] [Related]
7. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
[TBL] [Abstract][Full Text] [Related]
8. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
[TBL] [Abstract][Full Text] [Related]
9. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Beeslaar J; Mather S; Absalon J; Eiden JJ; York LJ; Crowther G; Maansson R; Maguire JD; Peyrani P; Perez JL
Vaccine; 2022 Mar; 40(12):1872-1878. PubMed ID: 35164991
[TBL] [Abstract][Full Text] [Related]
10. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
[TBL] [Abstract][Full Text] [Related]
11. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
12. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
Shirley M; Taha MK
Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
[TBL] [Abstract][Full Text] [Related]
13. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
14. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
[TBL] [Abstract][Full Text] [Related]
15. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
Pajon R; Lujan E; Granoff DM
Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
[TBL] [Abstract][Full Text] [Related]
16. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
17. Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.
Giuntini S; Lujan E; Gibani MM; Dold C; Rollier CS; Pollard AJ; Granoff DM
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847367
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
[TBL] [Abstract][Full Text] [Related]
19. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
Bettinger JA; Liberator P; Halperin SA; Vaudry W; Sadarangani M; Hao L; Lambert N; Jansen KU; Anderson AS; Tsang R;
Vaccine; 2020 Feb; 38(8):2026-2033. PubMed ID: 31983586
[TBL] [Abstract][Full Text] [Related]
20. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
Patton ME; Stephens D; Moore K; MacNeil JR
MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
